Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.InterMune announces Japanese approval of pulmonary fibrosis drug
Pirfenidone was developed in Japan for the treatment of idiopathic pulmonary fibrosis (IPF) by Shionogi, which has rights to pirfenidone in Japan, Taiwan and South Korea. InterMune has
Pirfenidone was developed in Japan for the treatment of idiopathic pulmonary fibrosis (IPF) by Shionogi, which has rights to pirfenidone in Japan, Taiwan and South Korea. InterMune has
A study is currently being conducted in the US wherein the site is actively screening and enrolling subjects. The protocol for the study is an open-label, two-treatment, two-period,
MedImmune will receive an upfront payment and has the potential to receive royalties on certain vaccine stockpiles or sales of other influenza products developed using the reverse genetics
Under the terms of the agreement, Philips and Celsion will collaborate to explore the potential for using Philips’s investigational magnetic resonance imaging-guided high intensity focused ultrasound (HIFU) system
Most recently, Mr Orville served as vice president of global sales for NextGen Sciences, an Ann Arbor, Michigan-based biomarker testing provider. Prior to joining NextGen, Mr Orville was
Under the terms of the agreement, Valeant purchased all of the outstanding shares of Coria from parent company, DFB Pharmaceuticals, and other shareholders for $95 million.
The Phase III clinical trial results on which this approval was based demonstrated that Abraxane doubled the response rate and significantly prolonged progression-free survival and overall survival versus
Preclinical in-vitro and in-vivo studies of RDEA119 have demonstrated synergistic activity across multiple tumor types when RDEA119 is used in combination with other anticancer agents, including sorafenib. This
The Phase II, multi-center, randomized, double-blind, placebo-controlled study is designed to assess the safety and efficacy of multiple doses of ACE-011 in multiple myeloma patients with osteolytic bone
Nicholas Stergis, CEO of Adeona, said: “As previously announced, we are pleased to have completed our corporate name and ticker symbol change. Our primary focus is toward the